Tenofovir is an acyclic nucleotide analogue reverse‐transcriptase inhibitor structurally
similar to the nephrotoxic drugs adefovir and cidofovir. Tenofovir is widely used to treat HIV …

Globally, in 2017 35 million people were living with HIV (PLHIV) and 257 million had chronic
HBV infection (HBsAg positive). The extent of HIV‐HBsAg co‐infection is unknown. We …

Tenofovir disoproxil fumarate (TDF), the first nucleotidic inhibitor of HIV reverse transcription,
became available in 2001. It has been extensively used worldwide and is now the most …

Importance of the field: Tenofovir (TFV) is a nucleotide analogue widely used for the
treatment of HIV infection. Despite its proven efficacy and safety, cases of kidney tubular …

Background. Tenofovir (TFV) causes kidney tubular dysfunction (KTD) in some patients, but
the mechanism is poorly understood. Genetic variants in TFV transporters are implicated; we …

Tenofovir disoproxil fumarate is currently the cornerstone of HIV treatment. Although it shows
an overall good safety profile, numerous cases of nephrotoxicity have been reported …

The introduction of highly active antiretroviral therapy (HAART) as standard of care has
changed the natural history of HIV infection into a manageable chronic disease requiring …

The introduction of HAART has represented a major advance in the care of people with HIV.
By markedly increasing life expectancy, HAART has significantly changed the pattern of HIV …

Abstract Background Tenofovir Disoproxil Fumarate (TDF) is one of the first-line antiretroviral
therapy (ART) recommended for all treatment naïve People Living with HIV (PLHIV) …

Background Previous WHO guidance on tenofovir disoproxil fumarate-based oral pre-
exposure prophylaxis (PrEP) suggests measuring creatinine levels at PrEP initiation and …